RP5063, also known as RP5000, is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder.    Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of  bipolar disorder, major depressive disorder, psychosis/ agitation associated with Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder (ADD/ADHD), and autism.  As of May 2015, it is in  phase III clinical trials for schizophrenia.  
Pharmacodynamics [edit ]
RP5063 is frequently described as a so-called "dopamine-serotonin system stabilizer" due to its unique actions on the
dopamine and serotonin neurotransmitter systems compared to other antipsychotics.  Specifically, it acts as a  partial agonist of the D, 2 D, and 3 D and of the 4 receptors 5-HT and 1A 5-HT, and as an 2A receptors antagonist of the 5-HT and 6 5-HT. 7 receptors   RP5063 has high  affinity for the D 2S, D 2L, D 3, D 4.4, 5-HT 1A, 5-HT 2A, 5-HT 7, and H, and moderate affinity for the 1 receptors D, 1 D, 5 5-HT, 5-HT 3 6 receptors, the SERT, and the α. 1B-adrenergic receptor It lacks significant affinity for the  5-HT, 1B 5-HT, 2C α, and 2-adrenergic mACh receptors, as well as for the NET and DAT.  
See also [edit ]
References [edit ]
^ Medicines in Development for Mental Health (PDF) (Report). Pharmaceutical Research and Manufacturers of America. 2014. p. 20 . Retrieved . 2015-05-19
^ Köster, Luisa-Sophie; Carbon, Maren; Correll, Christoph U (2014). "Emerging drugs for schizophrenia: an update". Expert Opinion on Emerging Drugs 19 (4): 511–531. doi: 10.1517/14728214.2014.958148. ISSN 1472-8214.
^ a b "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine 28 (5): 265–271. 2014. doi: 10.1007/s40290-014-0070-6. ISSN 1178-2595.
^ a b c Cantillon, Marc (2014). "Efficacy and Safety of Novel Dopamine Serotonin Stabilizer RP 5063 in Acute Schizophrenia and Schizoaffective Disorder". Schizophrenia Research 153: S22. doi: 10.1016/S0920-9964(14)70070-2. ISSN 0920-9964.
^ a b "About Us". Reviva Pharmaceuticals . Retrieved . 2015-05-19
^ a b "Product Pipeline". Reviva Pharmaceuticals . Retrieved . 2015-05-19
^ a b c d Marc Cantillon, M.D., Mike Li, MS, Sarath Kanekal, Ph.D., DABT, RAC, Robert M.J. Ings, Ph.D., Grace Tung, RAC, Laxminarayan Bhat (2013). "Refresh: A Phase 2 RP5063 Efficacy and Safety in Schizophrenia and Schizoaffective Disorder" (PDF). American Society of Clinical Psychopharmacology . Retrieved . 2015-05-19
^ Reviva Pharmaceuticals (2012). "Reviva Pharmaceuticals Announces Enrollment of Patients in Phase 2 Clinical Study of RP5063 for the Treatment of Schizophrenia and Schizoaffective Disorder". PipelineReview.
External links [edit ]
Non-generational: Atypical antipsychotics (e.g., aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone, zotepine)
Tetracyclic antidepressants (e.g., amoxapine, loxapine, maprotiline, mianserin, mirtazapine, oxaprotiline)
Tricyclic antidepressants (e.g., amitriptyline, butriptyline, clomipramine, desipramine, dosulepin (dothiepin), doxepin, imipramine, iprindole, lofepramine, nortriptyline, protriptyline, trimipramine)
Typical antipsychotics (e.g., chlorpromazine, flupenthixol, fluphenazine, loxapine, perphenazine, prochlorperazine, thioridazine, thiothixene)
Unknown/unsorted: Belarizine Elbanizine